《2015年HIV-1耐药性突变更新》
2015 Update of the Drug Resistance Mutations in HIV-1.
作者信息
Wensing Annemarie M, Calvez Vincent, Günthard Huldrych F, Johnson Victoria A, Paredes Roger, Pillay Deenan, Shafer Robert W, Richman Douglas D
机构信息
University Medical Center Utrecht, The Netherlands.
Pierre et Marie Curie University and Pitié-Salpêtrière Hospital, Paris, France.
出版信息
Top Antivir Med. 2015 Oct-Nov;23(4):132-41.
Abstract
The 2015 edition of the IAS-USA drug resistance mutations list updates the figures last published in July 2014. The mutations listed are those that have been identified by specific criteria for evidence and drugs described. The figures are designed to assist practitioners in identifying key mutations associated with resistance to antiretroviral drugs and, therefore, in making clinical decisions regarding antiretroviral therapy.
摘要
美国抗逆转录病毒学会（IAS-USA）2015年版耐药突变列表更新了上次于2014年7月发布的数据。列出的突变是根据针对所述证据和药物的特定标准确定的。这些数据旨在帮助从业者识别与抗逆转录病毒药物耐药性相关的关键突变，从而在抗逆转录病毒治疗方面做出临床决策。
相似文献
1
2015 Update of the Drug Resistance Mutations in HIV-1.
Top Antivir Med. 2015 Oct-Nov;23(4):132-41.
2
2017 Update of the Drug Resistance Mutations in HIV-1.
Top Antivir Med. 2016 Dec;24(4):132-133.
3
2019 update of the drug resistance mutations in HIV-1.
Top Antivir Med. 2019 Sep;27(3):111-121.
4
Update of the Drug Resistance Mutations in HIV-1.
Top HIV Med. 2008 Dec;16(5):138-45.
5
2022 update of the drug resistance mutations in HIV-1.
Top Antivir Med. 2022 Oct;30(4):559-574.
6
Update of the drug resistance mutations in HIV-1: Fall 2006.
Top HIV Med. 2006 Aug-Sep;14(3):125-30.
7
Update of the Drug Resistance Mutations in HIV-1: 2005.
Top HIV Med. 2005 Mar-Apr;13(1):51-7.
8
Update of the drug resistance mutations in HIV-1: Fall 2005.
Top HIV Med. 2005 Oct-Nov;13(4):125-31.
9
2011 update of the drug resistance mutations in HIV-1.
Top Antivir Med. 2011 Nov;19(4):156-64.
10
Short communication: low prevalence of genotypic drug resistance mutations among antiretroviral-naive HIV type 1 patients in Malaysia.
AIDS Res Hum Retroviruses. 2006 Feb;22(2):121-4. doi: 10.1089/aid.2006.22.121.
引用本文的文献
1
Sub- and supratherapeutic efavirenz plasma concentrations with risk for HIV therapy failure are mainly genetically explained in Ugandan children: The prospective GENEFA cohort study.
Br J Clin Pharmacol. 2025 Feb;91(2):464-478. doi: 10.1111/bcp.16272. Epub 2024 Oct 8.
2
Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure.
Clin Infect Dis. 2023 Nov 17;77(10):1423-1431. doi: 10.1093/cid/ciad370.
3
Evaluating whole HIV-1 genome sequence for estimation of incidence and migration in a rural South African community.
Wellcome Open Res. 2022 Jun 21;7:174. doi: 10.12688/wellcomeopenres.17891.1. eCollection 2022.
4
Prevalence and Structure of HIV-1 Drug Resistance to Antiretrovirals in the Volga Federal District in 2008-2019.
Viruses. 2022 Aug 27;14(9):1898. doi: 10.3390/v14091898.
5
Deep sequencing of HIV-1 reveals extensive subtype variation and drug resistance after failure of first-line antiretroviral regimens in Nigeria.
J Antimicrob Chemother. 2022 Feb 2;77(2):474-482. doi: 10.1093/jac/dkab385.
6
Non-B variants of HIV-1 in San Francisco, California.
Infect Genet Evol. 2021 Jun;90:104677. doi: 10.1016/j.meegid.2020.104677. Epub 2020 Dec 13.
7
A retrospective descriptive investigation of adult patients receiving third-line antiretroviral therapy in the North West province, South Africa.
Afr Health Sci. 2020 Jun;20(2):549-559. doi: 10.4314/ahs.v20i2.2.
8
Analysis of sequence diversity and selection pressure in HIV-1 clade C gp41 from India.
Virusdisease. 2020 Sep;31(3):277-291. doi: 10.1007/s13337-020-00595-x. Epub 2020 May 12.
9
Polymorphisms and drug resistance analysis of HIV-1 isolates from patients on first line antiretroviral therapy (ART) in South-eastern Nigeria.
PLoS One. 2020 Apr 8;15(4):e0231031. doi: 10.1371/journal.pone.0231031. eCollection 2020.
10
Prevalence of acquired drug resistance mutations in antiretroviral- experiencing subjects from 2012 to 2017 in Hunan Province of central South China.
Virol J. 2020 Mar 17;17(1):38. doi: 10.1186/s12985-020-01311-3.
本文引用的文献
1
2014 Update of the drug resistance mutations in HIV-1.
Top Antivir Med. 2014 Jun-Jul;22(3):642-50.
2
Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel.
JAMA. 2014;312(4):410-25. doi: 10.1001/jama.2014.8722.
3
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.
Lancet. 2013 Aug 24;382(9893):700-8. doi: 10.1016/S0140-6736(13)61221-0. Epub 2013 Jul 3.
4
Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness.
Antimicrob Agents Chemother. 2013 Jun;57(6):2654-63. doi: 10.1128/AAC.02568-12. Epub 2013 Mar 25.
5
Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir.
J Virol. 2012 Mar;86(5):2696-705. doi: 10.1128/JVI.06591-11. Epub 2011 Dec 28.
6
In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4.
Antiviral Res. 2012 Feb;93(2):288-296. doi: 10.1016/j.antiviral.2011.12.008. Epub 2011 Dec 16.
7
Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors.
J Med Virol. 2011 May;83(5):751-9. doi: 10.1002/jmv.22047. Epub 2011 Feb 25.
8
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.
Clin Infect Dis. 2008 Jul 15;47(2):266-85. doi: 10.1086/589297.
Zotero 插件